Weifeng Ding | Pancreatic Cancer | Best Researcher Award

Prof. Dr. Weifeng Ding | Pancreatic Cancer | Best Researcher Award

Affiliated Hospital of Nantong University | China

Author Profile

Scopus

📚 EARLY ACADEMIC PURSUITS

Dr. Ding Weifeng embarked on his academic journey with a strong foundation in medical laboratory science. His dedication to excellence and a deep interest in clinical research paved the way for advanced education, culminating in a Ph.D. His academic rigor was further enriched during his tenure as a Senior Visiting Scholar at the University of Texas Health Science Center (UTH) in the United States, where he gained international exposure and expertise.

🏆 PROFESSIONAL ENDEAVORS

Currently, Dr. Ding serves as the Deputy Director of the Department of Clinical Laboratory at the Affiliated Hospital of Nantong University and the Deputy Director of the Department of Laboratory Medicine at Nantong University. He holds dual roles as Chief Technologist, Associate Professor, and Master’s Supervisor, combining practical expertise, teaching, and mentorship in his field.

His professional career reflects significant recognition as a high-level talent under Jiangsu Province's "333" Project, a leading figure in Nantong City's "226" Project, and a key young medical talent in Jiangsu Province.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON PANCREATIC CANCER

Dr. Ding's research expertise spans medical laboratory science, with significant contributions in:

  • Advancing laboratory diagnostics.
  • Innovating approaches to translational medicine and molecular techniques.

He has successfully led three National Natural Science Foundation projects, a China Postdoctoral Science Foundation project, and seven provincial and municipal research projects. These projects demonstrate his ability to bridge clinical applications and theoretical research.

🌍 IMPACT AND INFLUENCE

Dr. Ding has gained widespread recognition for his contributions to scientific research, including the:

  • Third Prize of Jiangsu Medical Science and Technology Award
  • Second Prize of Nantong Science and Technology Progress Award
  • Nantong Youth Science and Technology Award

His achievements underscore his impact on the fields of clinical practice and scientific innovation.

📈 ACADEMIC CITATIONS AND SCHOLARLY IMPACT

Dr. Ding has authored nearly 30 SCI-indexed papers as the first or corresponding author, reflecting his leadership and originality in research. Furthermore, his five Chinese invention patents attest to his contributions to technological advancements in medical diagnostics.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Ding’s dedication to medical laboratory science has left a lasting legacy in education, innovation, and clinical practice. He actively fosters the next generation of professionals through mentorship and collaboration while pushing the frontiers of translational medicine and diagnostic technology.

In the years ahead, he is expected to:

  • Strengthen collaborations across global institutions.
  • Expand research projects in cutting-edge medical technologies.
  • Continue mentoring aspiring professionals in the medical laboratory field.

🌐 ENGAGEMENT IN ACADEMIC ORGANIZATIONS

Dr. Ding is actively involved in professional communities:

  • Standing Committee Member of the Abdominal Tumor Comprehensive Rehabilitation Branch, China Medical Education Association.
  • Committee Member of the Translational Medicine Professional Committee, Jiangsu Immunology Society.
  • Member of the Clinical Molecular Group, Jiangsu Medical Association Laboratory Medicine Branch.

📑NOTABLE PUBLICATIONS 

"Combined ultrasound endoscopy-guided fine-needle aspiration with DNA methylation of SHOX2 and RASSF1A genes to enhance the auxiliary diagnostic precision of pancreatic cancer

  • Authors: Shan, Y. , Teng, Y. , Guan, C. , Ding, W. , Zhang, J.
  • Journal: Heliyon
  • Year: 2024

"DNA methylation modulates epigenetic regulation in colorectal cancer diagnosis, prognosis and precision medicine

  • Authors: Ye, J., Zhang, J., Ding, W.
  • Journal: Exploration of Targeted Anti-tumor Therapy
  • Year: 2024

"Retraction Note: Targeting of colorectal cancer growth, metastasis, and anti-apoptosis in BALB/c nude mice via APRIL siRNA (Molecular and Cellular Biochemistry

  • Authors: Wang, J. , Ding, W. , Sun, B. , Shi, G. , Wang, H.
  • Journal: Molecular and Cellular Biochemistry
  • Year: 2023

"DNA hypermethylation contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 to the CPEB1 promoter

  • Authors: Shao, K. , Pu, W. , Zhang, J. , Zhang, Z. , Ding, W.
  • Journal: Clinical Epigenetics
  • Year: 2021

"Targeted Bisulfite Sequencing Reveals DNA Methylation Changes in Zinc Finger Family Genes Associated With KRAS Mutated Colorectal Cancer

  • Authors: Pu, W. , Qian, F. , Liu, J. , Ju, S. , Ding, W.
  • Journal: Frontiers in Cell and Developmental Biology
  • Year: 2021

Bruno Fuchs | Sarcoma | Excellence in Innovation

Prof Dr. Bruno Fuchs | Sarcoma | Excellence in Innovation 

Swiss Sacroma Network | Switzerland 

Author Profile

Orcid ID

Bruno Fuchs, MD, PhD 🌟

Position: Professor and Chair, Sarcoma Center & Swiss Sarcoma Network

Location: Faculty of Health Science & Medicine, University of Lucerne, and LUKS University Hospital, Luzern, Switzerland

Contact: fuchs@sarcoma.surgery

Educational Background 🎓

  • 2022: Guest-Professor, Medical Faculty, University of Lucerne
  • 2010: Extraordinarius, Medical Faculty, University of Zurich
  • 2005: Associate Professor, Medical Faculty, University of Zurich
  • 2004: PhD in Biomedical Sciences (Tumor Biology), Mayo Graduate School, Mayo College of Medicine, Rochester, MN, USA
  • 1996 - 2004: Training and Fellowship in Orthopedic Surgery and Musculoskeletal Oncology at Mayo Clinic, Rochester, MN, USA, and Swiss institutions
  • 1992: MD, Medical Faculty, University of Zurich, Switzerland

Clinical and Research Expertise 🔬

  • Specializes in the surgical treatment of bone and soft tissue tumors in both pediatric and adult patients
  • Focuses on outcome analysis and quality indicators in sarcoma care
  • Engages in predictive outcome analytics for improving sarcoma treatment

Academic Contributions 📚

  • Authored over 200 publications and book chapters
  • Acquired over 10 million Swiss Francs in research funding
  • Active as a reviewer for prestigious journals and grant committees

Contributions and Research Focus on Sarcoma🏆

Fuchs has made profound contributions to the surgical treatment of bone and soft tissue tumors in both pediatric and adult patients. His research is heavily focused on the outcome analysis of sarcoma patients, defining and assessing quality indicators of sarcoma care, and predictive outcome analytics. His work is vital in improving the standards and methodologies employed in sarcoma care, directly impacting patient outcomes and care quality.

Public and Professional Service 🌐

  • Founder & Chair of the Swiss Sarcoma Network
  • Founder of the Sarcoma Academy
  • Member of multiple medical societies including SwissOrthopaedics, FMH, and CTOS

Dr. Bruno Fuchs is recognized internationally for his extensive contributions to the field of sarcoma research and treatment. His work continues to shape the future of musculoskeletal oncology.

Notable Publications📑

"Real-World-Time Data and RCT Synergy: Advancing Personalized Medicine and Sarcoma Care through Digital Innovation" 

  • Authors: Philip Heesen, Georg Schelling, Mirko Birbaumer, Ruben Jäger, Beata Bode, Gabriela Studer, Bruno Fuchs
  • Journal: Cancers
  • Year: 2024

"Improving Sarcoma Outcomes: Target Trial Emulation to Compare the Impact of Unplanned and Planned Resections on the Outcome" 

  • Authors: Timothy T. A. F. Obergfell, Kim N. Nydegger, Philip Heesen, Georg Schelling, Beata Bode-Lesniewska, Gabriela Studer, Bruno Fuchs
  • Journal: Cancers
  • Year: 2024

"Impact of Institutional Practices and Surgical Complexity on Sarcoma Surgery Costs: Driving Efficiency in Value-Based Healthcare"

  • Authors: Georg Schelling, Philip Heesen, Boris Malte Tautermann, Markus Wepf, Barbara Di Federico, Annika Frei, Kim van Oudenaarde, Pietro Giovanoli, Beata Bode-Lesniewska, Gabriela Studer et al.
  • Journal: Cancers
  • Year: 2024

"Development and Validation of the Bone Tumor Surgery Complexity Score"

  • Authors: Annika Frei, Georg Schelling, Philip Heesen, Pietro Giovanoli, Bruno Fuchs
  • Journal: Reports
  • Year: 2024

"Exploring Risk Factors for Predicting 30-Day Postoperative Morbidity in Musculoskeletal Tumor Surgery"

  • Authors: Philip Heesen, Maria Elyes, Jan Domanski, Georg Schelling, Sören Könneker, Bruno Fuchs
  • Journal: Journal of Clinical Medicine
  • Year: 2024